Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application

Numerous macromolecular MRI contrast agents prepared employing relatively simple chemistry may be readily available that can provide sufficient enhancement for multiple applications. These agents operate using a ~100-fold lower concentration of gadolinium ions in comparison to the necessary concentration of iodine employed in CT imaging. Herein, we describe some of the general potential directions of macromolecular MRI contrast agents using our recently reported families of dendrimer-based agents as examples. Changes in molecular size altered the route of excretion. Smaller-sized contrast agents less than 60 kDa molecular weight were excreted through the kidney resulting in these agents being potentially suitable as functional renal contrast agents. Hydrophilic and larger-sized contrast agents were found better suited for use as blood pool contrast agents. Hydrophobic variants formed with polypropylenimine diaminobutane dendrimer cores created liver contrast agents. Larger hydrophilic agents are useful for lymphatic imaging. Finally, contrast agents conjugated with either monoclonal antibodies or with avidin are able to function as tumor-specific contrast agents, which also might be employed as therapeutic drugs for either gadolinium neutron capture therapy or in conjunction with radioimmunotherapy.

[1]  Wolfgang Ebert,et al.  Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[2]  H. Weinmann,et al.  Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography , 1999, Magnetic Resonance Materials in Physics, Biology and Medicine.

[3]  Hisataka Kobayashi,et al.  Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. , 2003, Bioconjugate chemistry.

[4]  Hisataka Kobayashi,et al.  Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. , 2003, Cancer research.

[5]  M. Brechbiel,et al.  Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. , 2002, Kidney international.

[6]  B. Misselwitz,et al.  Interstitial Magnetic Resonance Lymphography Using a Polymeric T1 Contrast Agent: Initial Experience With Gadomer-17 , 2002, Investigative radiology.

[7]  M. Brechbiel,et al.  Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). , 2002, Cancer research.

[8]  T. Iwanaga,et al.  Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.

[9]  R. Günther,et al.  T1-weighted MR-lymphography after intramammary administration of Gadomer-17 in pigs. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[10]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[11]  M. Brechbiel,et al.  Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.

[12]  Akira Hiraga,et al.  Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core , 2001, Magnetic resonance in medicine.

[13]  K Togashi,et al.  Positive effects of polyethylene glycol conjugation to generation‐4 polyamidoamine dendrimers as macromolecular MR contrast agents , 2001, Magnetic resonance in medicine.

[14]  M. Brechbiel,et al.  3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent , 2001, Magnetic resonance in medicine.

[15]  M. Brechbiel,et al.  Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine , 2001, Magnetic resonance in medicine.

[16]  M. Brechbiel,et al.  Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64). , 2001, Cancer research.

[17]  F. Vögtle,et al.  Dendrimers and Dendrons: Concepts, Syntheses, Applications , 2001 .

[18]  M. Brechbiel,et al.  Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. , 2001, Bioconjugate chemistry.

[19]  R Weissleder,et al.  Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. , 2001, Bioconjugate chemistry.

[20]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[21]  M. Brechbiel,et al.  Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.

[22]  G. Frija,et al.  MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[23]  Daniel H. S. Silverman,et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.

[24]  Martin W. Brechbiel,et al.  Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity , 2000, European Journal of Nuclear Medicine.

[25]  J. Im,et al.  Dynamic contrast-enhanced MR imaging of bacterial abscess and VX2 carcinoma in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. , 2000, AJR. American journal of roentgenology.

[26]  I. Pastan,et al.  Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. , 2000, Biological & pharmaceutical bulletin.

[29]  E C Wiener,et al.  Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. , 2000, Investigative radiology.

[30]  L. Gordon,et al.  Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  M. Brechbiel,et al.  Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.

[32]  T L Chenevert,et al.  Magnetic resonance angiography with gadomer-17. An animal study original investigation. , 1998, Investigative radiology.

[33]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[34]  E C Wiener,et al.  Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.

[35]  P. Sontum,et al.  Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers : Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents , 1997 .

[36]  N. van Bruggen,et al.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.

[37]  I. Pastan,et al.  L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. , 1996, Cancer research.

[38]  B. Hamm,et al.  Magnetic resonance lymphography in rats: effects of muscular activity and hyperthermia on the lymph node uptake of intravenously injected superparamagnetic iron oxide particles. , 1996, Academic radiology.

[39]  Shihua Zhao,et al.  Carboxymethyl-dextran-gadolinium-DTPA as a blood-pool contrast agent for magnetic resonance angiography. Experimental study in rabbits. , 1996, Investigative radiology.

[40]  D M Shames,et al.  Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. , 1996, Radiology.

[41]  M. Papisov,et al.  Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies. , 1996, Radiology.

[42]  R Weissleder,et al.  Targeted contrast agents in MR imaging. , 1996, Magnetic resonance imaging clinics of North America.

[43]  G. Frija,et al.  Capillary leakage of a macromolecular MRI agent, carboxymethyldextran-Gd-DTPA, in the liver: pharmacokinetics and imaging implications. , 1996, Magnetic resonance imaging.

[44]  R. Castellino,et al.  Characterization of Reactive Versus Tumor-Bearing Lymph Nodes with Interstitial Magnetic Resonance Lymphography in an Animal Model , 1995, Investigative radiology.

[45]  Wendy S. Becker,et al.  Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.

[46]  R. Weissleder,et al.  MR Lymphography with a Lymphotropic T1‐Type MR Contrast Agent: Gd‐DTPA‐PGM , 1995, Magnetic resonance in medicine.

[47]  R. Brasch,et al.  Contrast-Enhanced Magnetic Resonance Imaging Estimation of Altered Capillary Permeability in Experimental Mammary Carcinomas After X-Irradiation , 1994, Investigative radiology.

[48]  P. Singh,et al.  Starburst dendrimers: enhanced performance and flexibility for immunoassays. , 1994, Clinical chemistry.

[49]  T. Desser,et al.  Dynamics of tumor imaging with Gd‐DTPA—polyethylene glycol polymers: Dependence on molecular weight , 1994, Journal of magnetic resonance imaging : JMRI.

[50]  R. Weissleder,et al.  Detection of pulmonary emboli by using MR angiography with MPEG-PL-GdDTPA: an experimental study in rabbits. , 1994, AJR. American journal of roentgenology.

[51]  R. Brasch,et al.  Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.

[52]  R Weissleder,et al.  MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.

[53]  C. Meares,et al.  Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. , 1994, Cancer research.

[54]  Martin W. Brechbiel,et al.  Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .

[55]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[56]  R. Barth,et al.  Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. , 1994, Bioconjugate chemistry.

[57]  M. Taupitz,et al.  Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. , 1993, AJR. American journal of roentgenology.

[58]  A. Darkazanli,et al.  MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. , 1992, AJR. American journal of roentgenology.

[59]  M. Moseley,et al.  Magnetic Resonance Imaging Detection of an Experimental Pulmonary Perfusion Deficit Using a Macromolecular Contrast Agent: Polylysine–Gadolinium-DTPA40 , 1992, Investigative radiology.

[60]  B. Hamm,et al.  MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. , 1992, AJR. American journal of roentgenology.

[61]  R. Brasch,et al.  Rationale and applications for macromolecular Gd‐based contrast agents , 1991, Magnetic resonance in medicine.

[62]  J A Frank,et al.  Functional MR of the kidney , 1991, Magnetic resonance in medicine.

[63]  H. Weinmann,et al.  In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. , 1991, Investigative radiology.

[64]  M. Moseley,et al.  Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. , 1990, Radiology.

[65]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[66]  M. Moseley,et al.  Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. , 1989, Investigative radiology.

[67]  J A Frank,et al.  Gadolinium‐DTPA Enhanced Dynamic MR Imaging in the Evaluation of Cisplatinum Nephrotoxicity , 1989, Journal of computer assisted tomography.

[68]  J A Frank,et al.  Dynamic Gd-DTPA-enhanced MR imaging of the kidney: experimental results. , 1989, Radiology.

[69]  M. Ogan,et al.  Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.